Bio-Techne will invest $257 million in New Brighton med-tech company
The deal for 20% of Wilson Wolf is to expand the Minneapolis-based company's work with cell and gene therapies.
Stay updated with breaking news from Chuck Kummeth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The deal for 20% of Wilson Wolf is to expand the Minneapolis-based company's work with cell and gene therapies.
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2023.
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022. Second Quarter...
The company reported 1 percent growth in revenues compared to Q2 2022 but said organic revenue growth was 4 percent.
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth...